LAB Standard BioTools Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LAB

Price (delayed)

$0.7698

Market cap

$302.21M

P/E Ratio

3.5

Dividend/share

N/A

EPS

$0.22

Enterprise value

$60.27M

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 14
Relative Valuation: Rel. Valuation: 96
Relative Profitability: Rel. Profitability: 67

Standard BioTools Inc., has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable ...

Highlights
Standard BioTools's EPS has soared by 171% YoY and by 10% from the previous quarter
The company's net income has surged by 170% YoY and by 9% QoQ
Standard BioTools's equity has increased by 27% YoY but it has decreased by 3.8% QoQ
LAB's quick ratio is down by 26% from the previous quarter
Standard BioTools's gross profit has decreased by 5% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.fluidigm.com
Peers: RVTY QTRX PRPO MTD

Key stats

What are the main financial stats of LAB

LAB stock price

How has the Standard BioTools stock price performed over time
Intraday
5.45%
1 week
11.57%
1 month
16.28%
1 year
-45.4%
YTD
-39.86%
QTD
-6.43%

Financial performance

How have Standard BioTools's revenue and profit performed over time
Revenue
$84.6M
Gross profit
$42.71M
Operating income
-$95.47M
Net income
$84.91M
Gross margin
50.5%
Net margin
100.4%
The net margin has surged by 174% year-on-year and by 11% since the previous quarter
The company's net income has surged by 170% YoY and by 9% QoQ
LAB's operating income is up by 9% YoY
LAB's operating margin is up by 5% year-on-year

Price vs fundamentals

How does LAB's price correlate with its fundamentals

Growth

What is Standard BioTools's growth rate over time

Valuation

What is Standard BioTools stock price valuation
P/E
3.5
P/B
0.56
P/S
3.56
EV/EBIT
1.26
EV/EBITDA
1.02
EV/Sales
0.71
Standard BioTools's EPS has soared by 171% YoY and by 10% from the previous quarter
The price to book (P/B) is 38% lower than the last 4 quarters average of 0.9
Standard BioTools's equity has increased by 27% YoY but it has decreased by 3.8% QoQ
The P/S is 27% below the last 4 quarters average of 4.9
Standard BioTools's revenue has decreased by 4.8% YoY

Efficiency

How efficient is Standard BioTools business performance
The company's return on assets has surged by 172% YoY and by 5% QoQ
The ROE has soared by 167% YoY
Standard BioTools's ROS has soared by 142% YoY and by 21% from the previous quarter
The return on invested capital has surged by 138% year-on-year and by 18% since the previous quarter

Dividends

What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LAB.

Financial health

How did Standard BioTools financials performed over time
The current ratio has soared by 76% YoY but it is down by 26% from the previous quarter
LAB's total liabilities is down by 34% year-on-year but it is up by 12% since the previous quarter
The debt is 95% smaller than the equity
LAB's debt to equity is down by 29% year-on-year
Standard BioTools's equity has increased by 27% YoY but it has decreased by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.